1.30 0.00 (0.00%)
After hours: 4:49PM EST
|Bid||0.00 x 800|
|Ask||0.00 x 1300|
|Day's Range||1.2600 - 1.3400|
|52 Week Range||1.2200 - 3.1600|
|Beta (3Y Monthly)||2.98|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 7, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.10|
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced the publication of positive preclinical results which demonstrate that targeted intracerebral delivery of brain-derived neurotrophic factor utilizing HyStem®, BioTime’s proprietary hydrogel delivery platform technology, may mitigate ischemic brain injury and restore functional benefits by reducing neuroinflammation. The article entitled, “Intracerebral Delivery of Brain-Derived Neurotrophic Factor Using HyStem®-C Hydrogel Implants Improves Functional Recovery and Reduces Neuroinflammation in a Rat Model of Ischemic Stroke,” was published in the International Journal of Molecular Sciences and is authored by clinicians at the Stanford University School of Medicine, Department of Neurosurgery.
NEW YORK, Dec. 03, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
AgeX Therapeutics, Inc. (NYSE American: AGE), a biotechnology company focused on the development and commercialization of therapeutics targeting human aging, announced that its Founder and CEO Michael D. West, Ph.D. will present a keynote address at the Advanced Stem Cell & Regenerative Medicine conference 2018 in Valencia, Spain on Monday December 3, 2018. In his address, Dr. West will provide an update on AgeX product development, and will for the first time present data on the potential use of its proprietary induced Tissue Regeneration (iTRTM) technology in cancer diagnosis and therapy as well as in inducing the destruction of aged cells (a process known as “senolysis”). A copy of Dr. West’s presentation will be available on AgeX’s website at www.agexinc.com.
BioTime, Inc. , a clinical-stage biotechnology company focused on degenerative diseases, today announced that Brian M. Culley, Chief Executive Officer of BioTime will be presenting at the LD Micro 11th Annual Main Event Investor Conference on December 5th, 2018 at 8am Pacific Time at the Luxe Sunset Boulevard Hotel in Los Angeles, CA.
On November 28, 2018, AgeX’s former parent company, BioTime, Inc. (NYSE American: BTX) distributed approximately 12.7 million shares of AgeX common stock to BioTime shareholders in the ratio of one share of AgeX common stock for every 10 BioTime common shares owned. There are approximately 35.8 million shares of AgeX common stock outstanding of which approximately 1.7 million are held by BioTime and 16.4 million are held by Juvenescence Limited, a life science and biotech company developing therapies to increase healthy human longevity.
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that the registration statement on Form 10, including the information statement relating to the distribution that was previously prepared and filed by AgeX Therapeutics, Inc. (“AgeX”), was declared effective by the Securities and Exchange Commission (“SEC”) on November 27, 2018, and that BioTime will proceed with the distribution of approximately 12.7 million AgeX shares owned by BioTime on a pro rata basis, to eligible BioTime shareholders beginning at 5:00pm ET today. Eligible BioTime shareholders are entitled under the distribution to receive one share of AgeX common stock for every 10 shares of BioTime common stock held as of the record date of November 16, 2018.
Asterias Biotherapeutics, Inc. (NYSE American: AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular immunotherapies to treat cancer, today reported financial and operational results for the third quarter ended September 30, 2018. On November 7, 2018, Asterias entered into a merger agreement under which Asterias will become a wholly-owned subsidiary of BioTime, Inc. (NYSE American and TASE: BTX) and each outstanding share of common stock of Asterias not already owned by BioTime will be converted into 0.71 common shares of BioTime. The transaction is expected to close during the Company’s first quarter ending March 31, 2019, subject to the satisfaction of customary closing conditions.
NEW YORK, Nov. 08, 2018 -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Asterias Biotherapeutics, Inc. (NYSE: AST) on.
A look at the shareholders of BioTime Inc (NYSEMKT:BTX) can tell us which group is most powerful. Institutions will often hold stock in bigger companies, and we expect to see Read More...
On a per-share basis, the Alameda, California-based company said it had net income of 53 cents. Losses, adjusted for non-recurring gains, were 7 cents per share. The biotechnology company posted revenue ...
BioTime, Inc. (NYSE American and TASE: BTX), and Asterias Biotherapeutics, Inc. (“Asterias”) (NYSE American: AST), today announced that they have entered into a definitive merger agreement whereby BioTime will acquire all of the remaining outstanding common stock of Asterias that are not currently owned by BioTime. Asterias stockholders will receive 0.71 shares of BioTime common shares for every share of Asterias common stock and will own approximately 16.2% of the combined company.
ALAMEDA, Calif.-- -- Industry Veteran Brian M. Culley Appointed as CEO Signed Agreement to Acquire Asterias Biotherapeutics, Inc. Received $43.2 Million from AgeX Sale Transaction with Juvenescence Ltd. Positive OpRegen® Data Presented at 2018 American Academy of Ophthalmology Annual Meeting Date Set for Distribution of AgeX Therapeutics Shares to BioTime Stockholders BioTime, Inc. , a clinical-stage ...
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it has received the second installment payment of $10.8 million pursuant to the previously-announced sale of shares of AgeX Therapeutics Inc. (“AgeX”) to Juvenescence Limited (“Juvenescence”), a global leader in therapeutics focused on improving and extending human lifespans.
BioTime (BTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that it will report its third quarter 2018 financial and operating results on Thursday, November 8th, 2018, following the close of the U.S. financial markets. BioTime management will also host a conference call and webcast on Thursday, November 8th, 2018, at 4:30 p.m. Eastern Time/1:30 p.m. Pacific Time to discuss its third quarter 2018 financial results and to provide a business update. Interested parties may access the conference call by dialing (866) 888-8633 from the U.S. and Canada and (636) 812-6629 from elsewhere outside the U.S. and should request the “BioTime Inc. Call”.
BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced positive additional results from an ongoing Phase I/IIa study of its lead product candidate, OpRegen®, a retinal pigment epithelium cell therapy transplant currently in development for the treatment of dry form age-related macular degeneration (dry-AMD). The data were presented at the 2018 American Academy of Ophthalmology Annual Meeting (AAO 2018) on October 28th, 2018, in Chicago, Illinois, USA. Data from the study demonstrate that treatment with OpRegen® continues to be well tolerated and shows signs of structural improvement in the retina and decreases in drusen density in some patients.
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that its Board of Directors has set the record date for and distribution date for the distribution of AgeX Therapeutics (“AgeX”) shares owned by BioTime on a pro rata basis to eligible BioTime shareholders.
NEW YORK, Oct. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Abstract Selected to be Highlighted by the American Academy of Ophthalmology Organization Committee
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Russell Skibsted, Chief Financial Officer, will present at the upcoming MicroCap and Ladenburg Thalmann conferences. The MicroCap Conference will take place on October 1, 2018 at the Essex House in New York. The Ladenburg Thalmann 2018 Healthcare Conference will take place on October 2, 2018 at the Sofitel Hotel in New York.
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that Francois Binette, Senior Vice President and BioTime’s Head of Global Development, will participate in a panel discussion at the National Eye Institute Conference at 10:15am ET/7:15am PT on Tuesday, September 25, 2018 in Bethesda, Maryland. This conference is bringing together key academic and industry opinion leaders in the field of retinal disease regenerative medicine to discuss current state of science and clinical development, ongoing challenges and future directions to treat blindness. The discussion will be moderated by Ilyas Singec, National Center for Advancing Translational Services.
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, is advising the holders of its publicly traded warrants (NYSE American: BTX.WS) that the warrants will expire and not be exercisable after 5:00 p.m., New York City time, on October 1, 2018 (the “Expiration Date”). A warrant holder can obtain information on exercising the warrants by contacting their broker or American Stock Transfer & Trust Company, LLC., BioTime’s warrant agent.
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, today announced that the Board of Directors has implemented a new leadership structure under which Brian Culley has been appointed as the Company’s Chief Executive Officer and as a member of its Board of Directors, effective September 17, 2018. Mr. Culley succeeds Co-CEOs Adi Mohanty and Dr. Michael West.